Pre-Clinical Non-Viral Vectors Exploited for In Vivo CRISPR/Cas9 Gene Editing: An Overview

    January 2022 in “ Biomaterials Science ”
    Nadia Rouatbi, Tasneem McGlynn, Khuloud T. Al‐Jamal
    Studysummary Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubs.rsc.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Ultrasound-Activated Particles as CRISPR/Cas9 Delivery System for Androgenic Alopecia Therapy Biomaterials · 2019